Rodrigo Diaz M.
The National Vaccination Advisory Committee (NACI) has announced that it maintains its emergency recommendation to extend the administration of second doses of COVID-19 vaccines for up to four months.
NACI experts issued a recommendation in early March to extend the dosing interval from three to four weeks to a maximum of 16 weeks, because vaccine supplies were limited and they felt that some protection needed to be achieved for more people more quickly. .
In its follow-up recommendation, based on a more recent study of the vaccine, the NACI said it continues to believe this is the case.
“This helps provide direct protection to the individual and those around them and can also help prevent spread in the community.”
The expert group explained that it hopes that the administration of the second doses will not end up taking as long as the applications of the first dose, based on the vaccine supply planned in Canada.
The recommendation comes just as regulatory bodies in Europe and the UK have updated their analysis of the risk posed by the Oxford-AstraZeneca vaccine as it is related to blood clots in humans.
The European Medicines Agency (EMA) announced that it has enough evidence to believe that some types of blood clots are a rare side effect of the vaccine in a very small number of people, but they continue to believe that the benefits of The vaccine outweighs those risks because the threat from COVID-19 is even greater.
“COVID-19 is a very serious disease with high rates of hospitalization and death and every day COVID continues to cause thousands of deaths across the EU,” said EMA Executive Director Emer Cooke.
“This vaccine has proven to be very effective, it avoids the most serious symptoms and the risk of hospitalization, and it is saving lives.”
The EMA is putting blood clots on the label as a rare side effect of the vaccine, but is not advising that the vaccine not be given to any specific group.
Cooke claims that blood clots occur at a rate of between one in 100,000 people in Germany and one in 600,000 in the UK.
Although most cases have been seen in women under the age of 60, she says there have been clots in people of both genders and all age groups.
Canada stopped using the AstraZeneca vaccine in people under 55 years of age pending further study on it. It is not yet known if that recommendation will change.